 -In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the anti-inflammatory and immunomodulatory properties of LefamulinDUBLIN, Ireland, July 23, 2020 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today the results of a pre-clinical study demonstrating potent anti-inflammatory activity of lefamulin. In a mouse model of lipopolysaccharide LPS induced lung neutrophilia, lefamulin showed anti-inflammatory properties similar to dexamethasone, a corticosteroid commonly used for its anti-inflammatory and immunomodulatory properties. Lefamulin, the companys novel pleuromutilin antibiotic, is approved by the U.S. Food and Drug Administration FDA under the brand name XENLETA for the treatment of community-acquired bacterial pneumonia CABP in adults. XENLETA is the first IV and oral antibiotic with a novel mechanism of action approved by the FDA in nearly two decades. The study was accepted as a pre-print manuscript in bioRxiv.The research findings reflect the first study investigating the anti-inflammatory activity of lefamulin. In the mouse model of LPS induced lung neutrophilia, pretreatment with lefamulin at doses of 35, 70, and 140 mgkg administered subcutaneously SC 30 minutes before intranasal LPS administration challenge was associated with almost complete reduction in total cell and neutrophil recruitment to the lungs at 4 hours post challenge compared with the vehicle control group no treatment. Importantly, lefamulin demonstrated reductions in total cell and neutrophil counts that were similar to those observed with dexamethasone at all lefamulin doses tested. Nabriva has also been awarded grant funding from the Austrian Research Promotion Agency FFG as part of their Emergency Call for COVID-19 research. This funding will support additional in vitro and animal experiments designed to investigate and further characterize the anti-inflammatory and immunomodulatory properties of lefamulin, as well as our proprietary library of pleuromutilin compounds.The anti-inflammatory effect lefamulin demonstrated in this study is very encouraging, said Jennifer Schranz, MD, Chief Medical Officer of Nabriva. Inflammation complicates several pulmonary diseases including pneumonia and contributes substantially to morbidity and mortality in patients. We are excited to partner with the FFG to further investigate the anti-inflammatory and immunomodulatory properties of lefamulin and its potential application to inflammatory pulmonary diseases.Complete findings of the study titled Anti-inflammatory Activity of Lefamulin in a Lipopolysaccharide-Induced Lung Neutrophilia Model is available online at: Additional details about the FFG and the emergency call for COVID-19 research can be found at XENLETAXENLETA lefamulin is a first-in-class semi-synthetic pleuromutilin antibiotic for administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. XENLETAs binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP. In these trials, XENLETA was compared with moxifloxacin and in one trial, moxifloxacin with and without linezolid. Patients who received XENLETA had similar rates of efficacy as those taking moxifloxacin alone or moxifloxacin plus linezolid. The most common adverse reactions associated with XENLETA include diarrhea, nausea, reactions at the injection site, elevated liver enzymes, and vomiting.About Nabriva TherapeuticsNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA lefamulin injection, lefamulin tablets, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia CABP. XENLETA was discovered in Nabriva Therapeutics laboratories in Vienna, Austria. For more information, please visit the Austrian Research Promotion Agency FFGThe Austrian Research Promotion Agency FFG is the national funding agency for industrial research and development in Austria. The purpose of the FFG is to promote research, technology, development and innovation for the benefit of Austria. All FFG activities aim to strengthen Austria as a research and innovation center on the global market and thus help to ensure the long-term availability of high-quality jobs and maintain the prosperity of one of the worlds wealthiest countries. For more information, please visit AND IMPORTANT SAFETY INFORMATIONINDICATIONXENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia CABP caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus methicillin-susceptible isolates, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.USAGETo reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONSXENLETA is contraindicated in patients with known hypersensitivity to XENLETA or pleuromutilins.XENLETA tablets are contraindicated for use with CYP3A4 substrates that prolong the QT interval.WARNINGS AND PRECAUTIONSXENLETA has the potential to prolong the QT interval. Avoid XENLETA in patients with known QT prolongation, ventricular arrhythmias, and patients receiving drugs that may prolong the QT interval.Based on animal studies, XENLETA may cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.Clostridium difficile-associated diarrhea CDAD has been reported with nearly all systemic antibacterial agents, including XENLETA, with severity ranging from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.ADVERSE REACTIONSThe most common adverse reactions 2 for a XENLETA Injection are administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, and headache and b XENLETA Tablets are diarrhea, nausea, vomiting, and hepatic enzyme elevation.USE IN SPECIFIC POPULATIONSIn patients with severe hepatic impairment, reduce the dosage of XENLETA Injection to 150 mg infused over 60 minutes every 24 hours. XENLETA Tablets are not recommended in patients with moderate or severe hepatic impairment due to insufficient information to provide dosing recommendations.Avoid XENLETA Injection and Tablets with concomitant strong or moderate CYP3A or P-gp inducers. Monitor for reduced efficacy of XENLETA.Avoid XENLETA Tablets with strong CYP3A or P-gp inhibitors.Monitor for adverse reactions of sensitive CYP3A substrates administered with XENLETA Tablets.XENLETA has not been studied in pregnant women. Verify pregnancy status in females prior to initiating XENLETA and advise females to use contraception during treatment and for 2 days after the final dose. Lactating women should pump and discard milk for the duration of treatment with XENLETA and for 2 days after the final dose.To report SUSPECTED ADVERSE REACTIONS, or administration during pregnancy, contact Nabriva Therapeutics US, Inc. at 1-855-5NABRIVA or the FDA at 1-800-FDA-1088 or see Full Prescribing Information for XENLETA.Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about its ability to successfully launch and commercialize XENLETA for the treatment of CABP, including the availability of and ease of access to XENLETA through major U.S. 